Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.
Project Integrum is a large-scale R&D project designed to discover novel therapeutic antibodies for more than 1000 druggable targets. The project, which was initiated in March 2020, includes the following core milestones:
- Knock-out of 1000 pre-selected drug targets in RenMab TM and/or RenLite ® fully human antibody mice
- Leveraging these target KO RenMice (RenMice HiTS Platform) and high-throughput screening capabilities to establish an off-the-shelf library of fully human antibody hits exhibiting species cross-reactivity, as well as broader sequence and epitope diversity
- Streamlined identification of preclinical candidates (PCC) using Biocytogen’s innovative mouse models and in vivo/in vitro pharmacology platforms
- Development of antibody candidates into various drug modalities through joint or internal research, including monoclonal antibodies, bispecific antibodies, and ADCs.
The company has officially completed the first two milestones on schedule; nearly 1000 target KO RenMice® strains have been generated, more than 900 target antibody discovery projects have been completed, and a library containing 400-500K fully human antibody sequences has been established. 30+ PCC-stage molecules have also been successfully identified.
The rapid progress of the project has directly led to the exponential growth of Biocytogen’s antibody licensing and co-development business, with 50 antibody asset-based co-development/out-licensing/transfer agreements established, including partnerships with 6 multinational pharmaceutical companies. In addition, 5 collaborative products are expected to submit IND applications and start clinical trials in 2024. As the number of co-development products entering clinical trials increases, Biocytogen's ongoing business growth will be fueled not only by upfront payments but also by milestone payments.
As Project Integrum shifts focus to the latter milestones, the company will work with collaborators to expedite the development of selected antibodies against key targets to enter into the clinic.
Dr. Yuelei Shen, President and CEO of Biocytogen, said: “Project Integrum aims to overcome several difficulties in the field, such as crowded target selection and high cost, time-consuming antibody discovery. Species cross-reactive fully human antibodies derived from our platform can significantly reduce preclinical research time and cost, while improving the rate of translational success. We adopt an open, flexible and diverse business model to share our antibody repertoire and resources with global partners to reduce their development costs and increase the success rate by minimizing redundant investments and improving resource utilization efficiency. We welcome more collaborators to join us in this endeavor, working together to develop better antibody drugs that will benefit patients.”
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice® HiTS Platform). As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clarity AI Honored in Fast Company Magazine’s 2023 “Brands That Matter” List4.10.2023 10:24:00 EEST | Press release
Clarity AI, the leading sustainability technology platform, has been named to Fast Company’s prestigious annual list of “Brands That Matter” in 2023. With this list, Fast Company, the world's leading business media brand, aims to get beyond “corporate vision statements and management talking points” and recognize brands that “clearly generate enthusiasm among their customers, offering a model of what other brands should be aiming for, and what a brand, at its best, can achieve.” Clarity AI was selected among more than 1,000 entries for its contribution to allowing “companies, investors, and more to ensure they’re investing sustainably by tracking metrics ranging from data on the climate impact to gender equality and diversity on the executive boards of prominent companies.” Additionally, Fast Company highlights Clarity AI’s role in “improving artificial technologies and understanding the multitude of benefits they can offer.” Rebeca Minguela, Founder & CEO of Clarity AI, said: “We're h
Uusi kysely: 66% suomalaisista työntekijöistä haluaisi kotona työskentelystä lain suojaaman oikeuden4.10.2023 10:00:00 EEST | Tiedote
Yhteistyötä tukevia ratkaisuja tarjoavan tekniikkayrityksen Owl Labsin hiljattain toteuttama kysely selvittää pohjoismaisten työntekijöiden asennoitumista etätyöhön. The State of Hybrid Work Report 2023 -tutkimukseen osallistui 2 000 vastaajaa Suomesta, Ruotsista, Norjasta ja Tanskasta. Raportista selviää, että peräti 66% suomalaisista työntekijöistä haluaisi etätyöstä tehtävän lain suojaaman oikeuden. Tämä kertoo joustavien työolojen kasvavasta suosiosta. Tutkimuksen mukaan 63% kaikista pohjoismaisista työntekijöistä on samaa mieltä oikeudesta etätyöhön. Tuki etätyölle laillisena oikeutena jakautuu eri Pohjoismaissa seuraavasti: 65% ruotsalaisista, 63% norjalaisista ja 57% tanskalaisista työntekijöistä tukee ajatusta. Owl Labsin toimitusjohtaja Frank Weishaupt sanoo: “Pohjoismaisten työntekijöiden yksimielisyys kotona työskentelystä lain suojaamana oikeutena kertoo muutoksista työntekijöiden asenteissa työympäristöään kohtaan. Se vahvistaa, miten tärkeänä työn ja vapaa-ajan välistä ta
ABN AMRO and Motive Partners form strategic partnership4.10.2023 09:30:00 EEST | Press release
The move demonstrates a joint commitment from two sizable financial technology investors to support continued innovation and growth in the evolving fintech landscape. Motive Ventures, the early-stage venture arm of Motive Partners, will manage the ABN AMRO Ventures Fund (AAV), consisting of 15 early-stage companies. In addition, ABN AMRO will become a significant investor in Motive-managed vehicles. With funding in the financial services industry declining by 70% between 2021 and 2022, and numerous venture capitalists reducing their investment programmes, Motive Partners and ABN AMRO are charting a new course. Their partnership unites two leading venture platforms, each with decades of fintech expertise and a dedication to innovation in both financial services and venture capital. Their goal is to strengthen the fintech sector and boost innovation by bringing Motive Partners’ ecosystem and experts to the AAV portfolio and ABN AMRO’s broader network. Motive Ventures’ portfolio consists
Desktop Health Announces that Flexcera™ Smile Ultra+ is now Available in Europe, Following Recent Class IIa MDR Certification by the European Union4.10.2023 09:00:00 EEST | Press release
Desktop Health™, the trusted health care brand of Desktop Metal (NYSE:DM), announced that its popular Flexcera™ Smile Ultra+ dental resin, for 3D printing permanent and temporary restorations, is now available for purchase in Europe following its successful certification as a Class IIa medical device under the European Union Medical Device Regulation (MDR). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004075864/en/ Desktop Health's Flexcera™ Smile Ultra+ dental resin for 3D printing permanent and temporary restorations is now available for purchase in Europe following its successful certification as a Class IIa medical device under the European Union Medical Device Regulation (MDR). (Photo: Business Wire) Flexcera Smile Ultra+ delivers exceptional strength, life-like aesthetics, and the long-term performance expected from a permanent restoration material. Already an FDA 510(k) Class II cleared material, Flexcera Smile U
Velsera to Showcase Seven Bridges Bioinformatics Platform at BioTechX Europe4.10.2023 08:03:00 EEST | Press release
Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, is proud to announce its title sponsorship at BioTechX Europe in Basel, Switzerland, where it will showcase its industry-leading Seven Bridges bioinformatics platform. This conference is Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare. One of the keynote presentations, sponsored by Velsera, will be on the topic of “Digital Transformation of Early Research at Novo Nordisk and Leveraging AI/ML for Drug Discovery", featuring Asli Ismihan Ozen, head of research engineering, digital science and innovation at Novo Nordisk. She takes the stage at 9:20 am on Wednesday, Oct. 4. Additionally, Jack DiGiovanna, Velsera’s senior vice president of science strategy, will present on “Unleashing the Power of Neoantigens”, with an insightful look at solving complex problems through intero
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom